Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Autor: Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston., Oehler VG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington., Koller PB; Department of Hematology and Hematopoietic Cell Transplantation in the Division of Leukemia, City of Hope National Medical Center, Duarte, California., Jamy O; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham., Lomaia E; Research Department of Immuno-Oncology, Almazov Medical Research Centre, St Petersburg, Russian Federation., Hunter AM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Uspenskaya O; Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation., Samarina S; Kirov Scientific Research Institute of Hematology and Blood Transfusion of the FMBA, Kirov, Russian Federation., Mukherjee S; Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia., Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore., Zherebtsova V; S.P. Botkin City Clinical Hospital, Moscow, Russian Federation., Shuvaev V; A. Tsyb Medical Radiological Research Center, Obninsk, Russian Federation., Turkina A; National Medical Research Center for Hematology, Moscow, Russian Federation., Davydkin I; Samara State Medical University, Samara, Russian Federation., Guo H; Guangzhou Healthquest Pharma Co Ltd, Guangzhou, China., Chen Z; Ascentage Pharma (Suzhou) Co Ltd, Suzhou, China., Fu T; Ascentage Pharma Group Inc., Rockville, Maryland., Jiang L; Ascentage Pharma Group Inc., Rockville, Maryland., Wang C; Ascentage Pharma Group Inc., Rockville, Maryland., Wang H; Ascentage Pharma (Suzhou) Co Ltd, Suzhou, China., Yang D; Ascentage Pharma (Suzhou) Co Ltd, Suzhou, China.; Ascentage Pharma Group Inc., Rockville, Maryland.; Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhai Y; Guangzhou Healthquest Pharma Co Ltd, Guangzhou, China.; Ascentage Pharma (Suzhou) Co Ltd, Suzhou, China.; Ascentage Pharma Group Inc., Rockville, Maryland., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Nov 21. Date of Electronic Publication: 2024 Nov 21.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.

Autor: Wu, Andrew^1,2 (AUTHOR) awu@bccrc.ca, Liu, Xiaohu^1,2 (AUTHOR) wliu@virogin.com, Fruhstorfer, Clark¹ (AUTHOR), Jiang, Xiaoyan^1,2,3 (AUTHOR) xjiang@bccrc.ca

Publikováno v: International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 6, p3307. 23p.

Finding a new form of the grayling Thymallus arcticus (thymallidae) in the basin of lake baikal.

Autor: Knizhin, I., Weiss, S., Bogdanov, B., Samarina, S., Froufe, E.

Publikováno v: Journal of Ichthyology; Jan2006, Vol. 46 Issue 1, p34-43, 10p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.